The latest scientific findings onprotective effects of new metal-nonoates to the level of cardiovascular system cellsrecently published in the Journal of the American Society for Pharmacology and Experimental Therapeutics (JPET) are been chosen to feature in the next edition of Global Medical Discovery (GMD)
The paper entitled: "Protective Effects of Novel Metal-nonoates on the Cellular Components of the Vascular System" J. Pharmacol. Exp. Ther. 351: 500-509 (2014) shows that metal-nonoates, thanks to the release of nitric oxide modulated by metal ions, represent a significant innovation compared to currently used drugs. They have an effective dose up to 10 times lower than the reference compounds, inducing vascular integrity and an antihypertensive effect.
Global Medical Discovery exposes documents of exceptional scientific importance through about 845,000 monthly visits to a public in the field of academic, clinical and industrial R&D.
WELCOME IN NOXAMET
Here a brief description of Noxamet:
The academic spin-off Noxamet Ltd is a chemical/pharmaceutical enterprise established on July 2010 and accredited at the Universities of Pavia and Siena. In 2013, Noxamet was registered as innovative start up.
The core business of the enterprise is the preclinical development of new vasodilating and endothelium protective drugs [the "metal-nonoates", a new class of nitric oxide donors], to be primarily used in the treatment of cardiovascular diseases, but potentially applicable to other pathologies.
The design, synthesis, and physico-chemical characterization are carried out in the Noxamet chemical laboratory located in Pavia; while biological and pharmacological assays on the compounds are handled by the Life Sciences laboratory in Siena.
In addition to its core business, recently Noxamet started to develop its metal-nonoates in the agrochemical industry, as plant protecting agents against pathogens.
Noxamet Ltd is interested in collaborating with investigators from other pharmaceutical companies or public institutions in scientific projects aiming at developing new drugs or medical devices, or investigating specific signaling pathways.
Primarily, the company will focus on projects regarding the pharmacology of cardiovascular diseases and oncology. Of interest are also therapeutic strategies in wound healing and ocular pharmacology as well as bioavailability of synthetic biomaterials.
Here a brief video presentation of the project: